IAP Inhibitor Development Services for Bladder Cancer

Inquiry

The suppression of apoptosis in cancer tissues and tumor cell lines is attributed to the over-expression of anti-apoptosis genes. The gene family known as an inhibitor of apoptosis proteins (IAP) is crucial in regulating apoptosis. Alfa Cytology is committed to advancing bladder cancer research by offering comprehensive services for the development of IAP inhibitors.

Introduction to IAP Inhibitor

IAP is a group of anti-apoptotic factors in the apoptotic pathway that confer insensitivity to apoptotic stimulation upon cancer cells. Currently, eight IAPs have been identified in mammals, including X-linked inhibitor of apoptosis (XIAP), cellular IAP1 (cIAP1), cIAP2, Livin, IAP-like protein 2 (ILP2), neuronal apoptosis inhibitory protein (NAIP), Survivin and BRUCE. Recently, several members of the IAP family have been investigated within the context of bladder cancer, and some of these have exhibited correlations with specific clinical and pathological tumor features as well as prognosis.

IAP	Features
cIAP1	Nuclear cIAP1 expression may be strongly correlated with bladder cancer stage, grade, tumor recurrence, and tumor-related mortality.
Livin	Livin may be involved in the progression of superficial bladder cancer and could be used as a marker of early recurrence.
XIAP	XIAP may be considered to be an independent prognostic marker for the early recurrence of non-muscle-invasive bladder cancer.
Survivin	Survivin nuclear labeling index (Survivin-N) is a superior biological and prognostic marker for TaT1 urothelial carcinomas of the urinary bladder.

IAP blocks apoptosis through a number of different mechanisms.

Fig.1 IAPs block apoptotic signaling pathways, promoting prosurvival signaling. (Ferris, R. L., et al., 2023)

Our Services

Through cutting-edge research and state-of-the-art technology, Alfa Cytology delves into the intricate mechanisms of action underlying IAP inhibitors. Our expertise enables us to assist clients in developing groundbreaking IAP inhibitors, optimizing their efficacy, and identifying crucial biomarkers for a more targeted approach to bladder cancer therapies.

Target Identification and Validation

High-throughput Screening - Identify IAP targets using advanced screening technologies.
Biomarker Discovery - Validate biomarkers for IAP modulation and patient stratification.
In Vitro and In Vivo Models - Utilize bladder cancer cell lines and animal models to validate IAP targets.

Peptide and Protein-based Therapies

Peptide Design and Synthesis - Develop and optimize peptide inhibitors targeting IAPs.
Protein Engineering - Engineer fusion proteins and biologics to modulate IAP activity.
Stability and Delivery - Optimize stability and delivery methods for peptide and protein-based therapies.

Gene Therapy and RNA-based Approaches

RNA Interference - Develop siRNA and shRNA constructs to knock down IAP expression.
CRISPR/Cas9 - Utilize gene editing to disrupt IAP genes and enhance apoptosis.
mRNA Therapeutics - Develop mRNA-based therapies to modulate IAP expression and function.

Preclinical Testing and Evaluation

Efficacy Studies - Conduct in vitro and in vivo studies to evaluate the therapeutic potential of IAP inhibitors.
Safety and Toxicity Assessment - Perform comprehensive safety and toxicity testing in relevant preclinical models.
Pharmacokinetic and Pharmacodynamic Analysis - Analyze the pharmacokinetic and pharmacodynamic profiles of IAP inhibitors to inform dosing strategies.

Contact Us

Partner with Alfa Cytology to leverage our extensive expertise and cutting-edge technology in the development of IAP inhibitors for bladder cancer. Our tailored services are designed to meet your specific research needs, ensuring the highest quality and efficiency. If you require any assistance, please do not hesitate to contact us.

Reference

Ferris, R. L., Harrington, K., and et al. Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer treatment reviews, 2023, 113, 102492.

For research use only. Not intended for any clinical use.

Related Services

Solutions

Inquiry

* Name:

* Email:

Phone:

* Services:

Description:

* Please note that we are not a pharmacy or clinic, so we do not offer diagnostic and treatment services for patients.

* Tick to confirm the Research Use Only (RUO) statement.